Does Tirzepatide Cause Hair Loss? What the Evidence Shows

Hair loss has been reported during tirzepatide treatment. Zepbound’s US prescribing information lists it as an adverse reaction associated with weight reduction. That finding does not establish that tirzepatide directly damages hair follicles or explain every person’s shedding. 1

If you notice more hair falling out, tell the clinician managing your prescription. A dermatologist can help identify the cause, including whether more than one condition is involved. 7

What does the Zepbound label report?

In pooled weight-reduction Studies 1 and 2, involving adults with obesity or overweight with or without type 2 diabetes, the label reports: 1

Study group	Participants reporting hair loss
Zepbound 5 mg	5%
Zepbound 10 mg	4%
Zepbound 15 mg	5%
Placebo	1%

Across those studies, reports were more frequent in female participants: 7.1% with Zepbound versus 1.3% with placebo. The corresponding figures for male participants were 0.5% and 0%. These are the label’s reported sex categories, not personalized risk estimates. 1

The original 72-week SURMOUNT-1 trial, which excluded diabetes, reported alopecia in 5.1%, 4.9% and 5.7% of the tirzepatide 5, 10 and 15 mg groups, versus 0.9% with placebo. Alopecia means hair loss; that trial table did not identify every event’s specific hair-loss diagnosis. Its single-trial figures differ from the label’s two-study pool. 3

These dose groups describe research, not instructions for adjusting a prescription to manage shedding.

What about Mounjaro?

Mounjaro also contains tirzepatide. Its current US label lists alopecia among postmarketing reports. These voluntary reports come from a population of uncertain size, so they cannot reliably establish how often it happens or whether the medicine caused it. 2

A Zepbound study percentage should not be presented as a measured Mounjaro rate. Different product indications, populations and evidence types matter. Confirm the exact product with your prescriber rather than treating every tirzepatide preparation as interchangeable.

Does this prove a direct drug effect?

The trial findings show that hair loss occurred more often in treated groups, but they do not isolate a direct effect on follicles from the effects of weight reduction or other changes during treatment.

A 2026 retrospective study used electronic health records to compare adults with type 2 diabetes or obesity who used GLP-1 medicines with matched nonusers. Tirzepatide was associated with higher odds of nonscarring hair loss and telogen effluvium, a shedding condition. People with hair-loss outcomes also had lower follow-up body mass index. The authors suggested weight-loss-related physiological stress may contribute. 4

That is observational evidence. Matching people on recorded characteristics cannot remove every difference between them, and a recorded diagnosis does not prove why an individual’s hair changed. The study does not supply a test that can identify tirzepatide as the cause in a particular person.

How can weight loss affect hair shedding?

Telogen effluvium is excessive shedding that can follow a physical or emotional stressor, including substantial weight loss. It may become noticeable months after the triggering event. This delay means the date you notice shedding may differ from the date of the contributing change. 6

An original study reviewed 140 patients diagnosed with telogen effluvium associated with weight loss. It supports weight loss as a relevant part of the history, but it was a single-center retrospective study with recall and selection limitations. It was not a tirzepatide trial and cannot define a safe weight-loss speed or a threshold below which shedding will not occur. 5

Weight loss is one possible contributor. Illness, childbirth, stress, hereditary hair loss and other medicines can also matter; shedding and another hair-loss condition can coexist. A change during medication use deserves assessment rather than an automatic diagnosis of telogen effluvium. 6, 7

Will the hair grow back?

Some stress-related shedding improves after the trigger resolves. Ongoing triggers or another hair-loss condition can change the course. The general recovery pattern for telogen effluvium is not a promise about hair loss during tirzepatide treatment. 6

The evidence above does not establish an individual regrowth deadline, guarantee recovery after stopping, or show that a supplement routine prevents shedding. Ask what diagnosis is most likely and what improvement or worsening should prompt reassessment.

What should you discuss with a health professional?

A useful starting point is a short timeline. Bring your medication name, when treatment began, when you first noticed shedding, recent weight changes, illnesses, eating changes, other medicines and supplements, and any previous hair thinning. Describe whether the change is widespread, concentrated in patches or accompanied by scalp symptoms.

A dermatologist’s assessment may include your history, scalp examination and hair testing. Blood tests or a scalp biopsy may be considered when the suspected cause warrants them; every person does not need the same test panel. 7

Use the visit to ask:

• Does this look like shedding, another form of hair loss, or more than one problem?
• Could a health condition, another medicine or a nutritional deficiency be contributing?
• Is an examination or targeted testing appropriate?
• What should I monitor, and when should we reassess?
• How should I handle my prescription while you investigate?

You do not need to wait for a set number of months to raise a concern. Finding the cause guides whether treatment is needed and which options fit. 7

Contact your prescriber about the hair change, and ask whether a dermatologist’s assessment would help. Agree on a follow-up plan before changing your prescription because of shedding. 6

Sources

1. Zepbound US prescribing information, Eli Lilly and Company. Revised August 2026; section 6.1. Checked October 24, 2026.
2. Mounjaro US prescribing information, Eli Lilly and Company. Revised August 2026; sections 1 and 6.2. Checked October 24, 2026.
3. Tirzepatide Once Weekly for the Treatment of Obesity, Jastreboff AM et al., New England Journal of Medicine, 2022;387:205–216. SURMOUNT-1, Table 4. Checked October 24, 2026.
4. Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study, Katragadda R et al., The Laryngoscope, published online August 26, 2026. Original-study abstract checked October 24, 2026.
5. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study, Kang DH et al., Annals of Dermatology, 2024;36:384–388. Checked October 24, 2026.
6. Do you have hair loss or hair shedding?, American Academy of Dermatology. Checked October 24, 2026.
7. Hair loss: Diagnosis and treatment, American Academy of Dermatology. Checked October 24, 2026.